A Highly Sensitive Bead-based Flow Cytometric Competitive Binding Assay to Detect SARS-CoV-2 Neutralizing Antibody Activity

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Dec 19

PMID 36532082

Authors

Xiangyu Yao

Zhichao Zhang

Qingmin Mei

Shenwei Li

Li Xing

Yali Long

Demei Zhang

Jing Wang

Xiedong Wang

Bin Xie

Bo Yang

Yong Gao

Changxin Wu

Qinglai Meng

Affiliations

Soon will be listed here.

Abstract

Accurate detection of SARS-CoV-2 neutralizing antibody (nAb) is critical for assessing the immunity levels after virus infection or vaccination. As fast, cost-effective alternatives to viral infection-based assays, competitive binding (CB) assays were developed to quantitate nAb by monitoring the ability of sera to inhibit the binding of viral spike (S) protein to the angiotensin converting enzyme 2 (ACE2) receptor. Herein, we established a bead-based flow cytometric CB assay and tested the detection performance of six combination models, i.e. immobilized ACE2 and soluble Fc-tagged S1 subunit of S protein (iACE2/S1-Fc), immobilized ACE2 and soluble Fc-tagged receptor binding domain (RBD) of S protein (iACE2/RBD-Fc), immobilized S1 and soluble Fc-tagged ACE2 (iS1/ACE2-Fc), immobilized S1 and soluble His-tagged ACE2 (iS1/ACE2-His), immobilized RBD and soluble Fc-tagged ACE2 (iRBD/ACE2-Fc), and immobilized RBD and soluble His-tagged ACE2 (iRBD/ACE2-His). Using SARS-CoV-2 monoclonal antibodies and sera of convalescent COVID-19 patients and vaccinated subjects, the combination models iACE2/RBD-Fc, iACE2/S1-Fc and iS1/ACE2-His were identified to be able to specifically detect SARS-CoV-2 nAb, among which iACE2/RBD-Fc model showed the highest sensitivity, superior to a commercial SARS-CoV-2 surrogate virus neutralization test (sVNT) ELISA kit. Further studies demonstrated that the sensitivity and specificity of CB assays were affected by the tag of ACE2, type of spike and method of measuring binding rate between ACE2 and spike. Moreover, the iACE2/RBD-Fc model showed good performance in detecting kinetic development of nAb against both the prototype SARS-CoV-2 strain and an omicron variant of SARS-CoV-2 in people immunized by an inactivated SARS-CoV-2 vaccine, and the results of iACE2/RBD-Fc model are correlated well with those of live virus-based and pseudovirus-based neutralization tests, demonstrating the potential to be developed into a highly sensitive, specific, versatile and high-throughput method for detecting SARS-CoV-2 nAb in clinical practice.

References

Heggestad J, Britton R, Kinnamon D, Wall S, Joh D, Hucknall A . Rapid test to assess the escape of SARS-CoV-2 variants of concern. Sci Adv. 2021; 7(49):eabl7682. PMC: 8641938. DOI: 10.1126/sciadv.abl7682. View

Thijssen M, Devos T, Ejtahed H, Amini-Bavil-Olyaee S, Pourfathollah A, Pourkarim M . Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases. Microorganisms. 2020; 8(11). PMC: 7694357. DOI: 10.3390/microorganisms8111733. View

Mravinacova S, Jonsson M, Christ W, Klingstrom J, Yousef J, Hellstrom C . A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies. N Biotechnol. 2021; 66:46-52. PMC: 8495044. DOI: 10.1016/j.nbt.2021.10.002. View

Tan C, Chia W, Qin X, Liu P, Chen M, Tiu C . A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020; 38(9):1073-1078. DOI: 10.1038/s41587-020-0631-z. View

Du L, Yang Y, Zhang X . Neutralizing antibodies for the prevention and treatment of COVID-19. Cell Mol Immunol. 2021; 18(10):2293-2306. PMC: 8424621. DOI: 10.1038/s41423-021-00752-2. View

Ding C, He J, Zhang X, Jiang C, Sun Y, Zhang Y . Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies. Front Immunol. 2021; 12:693775. PMC: 8416052. DOI: 10.3389/fimmu.2021.693775. View

Walker S, Chokkalingam N, Reuschel E, Purwar M, Xu Z, Gary E . SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients. J Clin Microbiol. 2020; 58(11). PMC: 7587116. DOI: 10.1128/JCM.01533-20. View

Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q . Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020; 367(6485):1444-1448. PMC: 7164635. DOI: 10.1126/science.abb2762. View

Zhang X, Zheng M, Wang H, Zhou H, Liang T, Zhang J . Inhibitor screening using microarray identifies the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and vaccination. Theranostics. 2022; 12(6):2519-2534. PMC: 8965487. DOI: 10.7150/thno.67038. View

10.

Ai J, Zhang H, Zhang Y, Lin K, Zhang Y, Wu J . Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect. 2021; 11(1):337-343. PMC: 8788341. DOI: 10.1080/22221751.2021.2022440. View

11.

Meyer B, Reimerink J, Torriani G, Brouwer F, Godeke G, Yerly S . Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT). Emerg Microbes Infect. 2020; 9(1):2394-2403. PMC: 7605318. DOI: 10.1080/22221751.2020.1835448. View

12.

Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S . Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020; 581(7807):215-220. DOI: 10.1038/s41586-020-2180-5. View

13.

Xiao T, Lu J, Zhang J, Johnson R, McKay L, Storm N . A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent. Nat Struct Mol Biol. 2021; 28(2):202-209. PMC: 7895301. DOI: 10.1038/s41594-020-00549-3. View

14.

Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L . Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2021; 22(4):483-495. PMC: 8651254. DOI: 10.1016/S1473-3099(21)00681-2. View

15.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

16.

Fenwick C, Turelli P, Pellaton C, Farina A, Campos J, Raclot C . A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma. Sci Transl Med. 2021; 13(605). PMC: 9835890. DOI: 10.1126/scitranslmed.abi8452. View

17.

Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M . A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020; 369(6504):650-655. PMC: 7319273. DOI: 10.1126/science.abc6952. View

18.

Liu L, Wang P, Nair M, Yu J, Rapp M, Wang Q . Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020; 584(7821):450-456. DOI: 10.1038/s41586-020-2571-7. View

19.

Yu X, Wei D, Xu W, Liu C, Guo W, Li X . Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern. Nat Commun. 2022; 13(1):1788. PMC: 8980020. DOI: 10.1038/s41467-022-29477-0. View

20.

Carreno J, Alshammary H, Tcheou J, Singh G, Raskin A, Kawabata H . Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature. 2022; 602(7898):682-688. DOI: 10.1038/s41586-022-04399-5. View